-
-
- 소 속: 분당차병원
-
전문분야
: 간암/췌담도암
- 직 위: 부교수(암센터장)
- 메 일: 비공개
- 전 화: 1577-4488
- 팩 스:
- 주 소: 경기도 성남시 분당구 야탑동 351번지
- 홈페이지:
탭메뉴
주요발표논문
| 번호 |
구분 |
제목 |
다운로드 |
| 75 |
해외 |
Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ*, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology 2020 (IF 20.582) (*Co-corresponding author) |
|
| 74 |
해외 |
Lee YS, Lee WS, Kim CW, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, Chon HJ*, Kim C. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with PD-1 blockade to suppress peritoneal carcinomatosis in colon cancer. J Immunother Cancer 2020 (In Revision) (IF 9.9) (*Co-corresponding author) |
|
| 73 |
해외 |
Cheon JK*, Chon HJ*, Bang Y, Park NK, Shin JW, Kim KM, Lee Han Chu, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis Liver Cancer 2020 (IF 9.720) (*Co-first author) |
|
| 72 |
해외 |
Chae HJ, Jeong HH, Cheon JK, Chon HJ, Ryu HW, Kim IH, Kang MJ, Jeong JH, Ryoo BY, Kim KP, Yoo CH. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis Therapeutic Advances in Medical Oncology 2020 |
|
| 71 |
해외 |
Chon HJ, and C Kim. REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. Chinese Clinical Oncology 2020 (first author) |
|
| 70 |
해외 |
Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, Kim S, Kim G, Chon HJ*, and C Kim. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. The Journal of Clinical investigation 2019 (IF 12.282) (*Co-corresponding author) |
|
| 69 |
해외 |
Chon HJ*, Kim HJ*, Noh JH, Yang HN, Lee WS, Kong SJ, Lee SJ, Lee YS, Kim WR, Kim JH, Kim, GI, and Kim C. STING signaling is a potential immunotherapeutic target in colorectal cancer. Journal of Cancer 2019 (IF 3.182) (*Co-first author) |
|
| 68 |
해외 |
Yoo CH, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kim IH, Lee GJ, Oh SY, Choi YN, Cho HJ, Kim ST, Park JH, and Ryoo BY. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology 2019 (IF: 5.67) |
|
| 67 |
해외 |
Kim C*, Chon HJ*, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. European Journal of Cancer 2019 (IF 7.191) (*Co-first author) |
|
| 66 |
해외 |
Chon HJ*, Lee WS*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. Clinical Cancer Research 2019 (IF 10.199) |
|
1
2
3
4
5
6
7
8
Copyright ⓒ chamc, All rights reserved.
